XML 47 R33.htm IDEA: XBRL DOCUMENT v3.25.3

Derivative Liability (Tables)

9 Months Ended

Sep. 30, 2025

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Warrant Liabilities

The key inputs for the Series A warrant liabilities were as follows:

 Schedule of Derivative Warrant Liabilities  

Warrant Liability – Series A Warrants		January 17, 2025				December 31, 2024
Stock price on valuation date		$	8.38			$	18.00
Exercise price		$	8.38			$	34.00
Number of shares of common stock			1,133,652				279,412
Remaining term (years)			4.88				4.93
Annual equity volatility			126.0	%			113.0	%
Annual volume volatility			377.0	%			379.0	%
Risk-free interest rate			4.32	%			4.29	%
Expected stockholder approval date			January 13, 2025				January 14, 2025
Expected stockholder approval probability			100	%			50	%

Schedule of Fair Value of the Derivative Liabilities

The following table provides a roll-forward of the fair value of the derivative liabilities described above during the nine months ended September 30, 2025:

 Schedule of Fair Value of the Derivative Liabilities  

		Series A Warrants				Series B Warrants				Total Warrant Liabilities
Balance at December 31, 2024		$	5,456,000			$	11,147,000			$	16,603,000
Balance		$	5,456,000			$	11,147,000			$	16,603,000
Exercises			—				(15,214,000	)			(15,214,000	)
Loss on change in fair value			2,401,000				4,067,000				6,468,000
Reclassification to equity			(7,857,000	)			—				(7,857,000	)
Balance at September 30, 2025		$	—			$	—			$	—
Balance		$	—			$	—			$	—

Schedule of Shares of Common Stock Underlying Warrants

The following table provides a roll-forward of the number of warrants issued during the nine months ended September 30, 2025:

Schedule of Shares of Common Stock Underlying Warrants 

		Series A Warrants				Series B Warrants				Other Warrants				Total
Balance at December 31, 2024			279,412				279,412				4,511				563,335
Balance			279,412				279,412				4,511				563,335
Exercises			—				(279,412	)			—				(279,412	)
Balance at September 30, 2025			279,412				—				4,511				283,923
Balance			279,412				—				4,511				283,923

The Company did not issue any warrants during the three and nine months ended September 30, 2024 and did not have any warrants outstanding as of September 30, 2024.

X

- References

No definition available.

+ Details

Name:	us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of derivative liabilities at fair value.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B

+ Details

Name:	us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482425/460-10-50-8

+ Details

Name:	us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

+ Details

Name:	us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration